CAS
TCRX icon

CTC Alternative Strategies’s TScan Therapeutics TCRX Stock Holding History

CTC Alternative Strategies’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-11,000
Closed -$87.3K – 271
2024
Q1 		$87.3K Buy
+11,000
New +$69.2K 0.05% 81

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

CTC Alternative Strategies's TCRX Position: Q2 2024 in Review

CTC Alternative Strategies sold out of TScan Therapeutics (TCRX) in Q2 2024, closing a stake of 11,000 shares — an estimated $87.3K sold.

CTC Alternative Strategies first reported a position in TCRX in Q1 2024 and held it in 1 quarter. The position peaked at $87.3K in Q1 2024. 80 funds tracked by Wall St. Rank hold TCRX as of Q2 2024.

  • CTC Alternative Strategies reported no remaining TScan Therapeutics position as of Q2 2024 after selling out during the quarter.
  • CTC Alternative Strategies sold 11,000 TScan Therapeutics shares in Q2 2024, an estimated $87.3K.
  • CTC Alternative Strategies first reported a position in TScan Therapeutics in Q1 2024 and held it in 1 quarter.
  • CTC Alternative Strategies's TScan Therapeutics position peaked at $87.3K in Q1 2024.
  • 80 funds tracked by Wall St. Rank held TScan Therapeutics as of Q2 2024.

Based on CTC Alternative Strategies's 13F filing for Q2 2024, filed 2 Aug 2024.